|Tested species reactivity||Human, Mouse, Rat|
|Published species reactivity||Not Applicable|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A 15 amino acid peptide near the carboxy terminus of human TMEM184B.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||20 ug/ml|
|Immunofluorescence (IF)||20 ug/ml|
|Immunohistochemistry (IHC)||5 µg/ml|
|Western Blot (WB)||1-2 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 1 publications below|
A suggested positive control is rat lung tissue lysate.
PA5-20932 can be used with blocking peptide PEP-1046.
TMEM184B, also known as C22orf5, is a 407 amino acid multi-pass membrane protein and represents a novel gene in the activation of the MAPK signaling pathway. The gene encoding TMEM184B maps to human chromosome 22; mutations in several of the genes in chromosome 22 are involved in the development of autism, schizophrenia, Phelan-McDermid syndrome and Neurofibromatosis type 2, suggesting that TMEM184B may play a role in these syndromes.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
MicroRNA expression signature of oral squamous cell carcinoma: functional role of microRNA-26a/b in the modulation of novel cancer pathways.
PA5-20932 was used in western blot to analyze microRNA expression in oral squamous cell carcnioma to determine the functional role of microRNA-26a/b in regulation of novel cancer pathways
|Fukumoto I,Hanazawa T,Kinoshita T,Kikkawa N,Koshizuka K,Goto Y,Nishikawa R,Chiyomaru T,Enokida H,Nakagawa M,Okamoto Y,Seki N||British journal of cancer (112:891)||2015|